BRPI0602397A - uso e formulações de agentes nitrosantes para o tratamento da doença gordurosa do fìgado - Google Patents
uso e formulações de agentes nitrosantes para o tratamento da doença gordurosa do fìgadoInfo
- Publication number
- BRPI0602397A BRPI0602397A BRPI0602397-5A BRPI0602397A BRPI0602397A BR PI0602397 A BRPI0602397 A BR PI0602397A BR PI0602397 A BRPI0602397 A BR PI0602397A BR PI0602397 A BRPI0602397 A BR PI0602397A
- Authority
- BR
- Brazil
- Prior art keywords
- nitrosothiols
- formulations
- treatment
- specifically
- action
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 210000004185 liver Anatomy 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 4
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000051 modifying effect Effects 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000007863 steatosis Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
USO E FORMULAçõES DE AGENTES NITROSANTES PARA O TRATAMENTO DA DOENçA GORDUROSA DO FìGADO. A presente invenção se refere a formulações contenda como princípios ativos os S-nitrosotióis, destinadas ao tratamento, por via oral, da doença gordurosa não alcoólica do fígado. Mais especificamente, uso terapêutico destas formulações se caracteriza como uma nova abordagem no tratamento de doenças do fígado, especificamente da doença gordurosa não alcoólica do fígado, que abrange desde a esteatose benigna sem inflamação, até a esteatohepatite com fibrose e a cirrose. Mais especificamente ainda a presente invenção apresenta um novo mecanismo de ação do princípio ativo das formulações, que não se baseia apenas na ação anti-oxidante dos S-nitrosotióis, mas também em sua ação nitrosante, capaz de modificar a atividade de enzimas envolvidas na síntese e transporte de lipídeos no fígado. Nenhum antioxidante clássico é capaz de exercer estas ações modificadoras dos S-nitrosotióis, uma vez que elas estão associadas à presença da molécula de óxido nítrico nos S-nitrosotióis e à capacidade destes compostos transferirem o óxido nítrico para moléculas receptoras (como enzimas e outras proteínas) em reações de transnitrosação. Esta característica é única dos S-nitrosotióis, o que permite classificar estes compostos como agentes nitrosantes.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRC10602397-5A BRPI0602397C1 (pt) | 2006-04-20 | 2006-04-20 | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições |
| US12/226,406 US20100062059A1 (en) | 2006-04-20 | 2007-04-20 | S-Nitrosothiols Containing Composition for the Treatment of Fatty Liver Diseases, Obesity and Other Diseases Associated with the Metabolic Syndrome and the Use of Such Compositions |
| PCT/BR2007/000099 WO2007121545A1 (en) | 2006-04-20 | 2007-04-20 | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions |
| EP07719267A EP2010164A4 (en) | 2006-04-20 | 2007-04-20 | COMPOSITIONS CONTAINING S-NITROSOTHIOLE AND THEIR USE FOR THE TREATMENT OF FATTLEBER, FAT LEVEL AND OTHER DISORDERS ASSOCIATED WITH METABOLIC SYNDROME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRC10602397-5A BRPI0602397C1 (pt) | 2006-04-20 | 2006-04-20 | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0602397A true BRPI0602397A (pt) | 2007-12-18 |
| BRPI0602397C1 BRPI0602397C1 (pt) | 2009-11-24 |
Family
ID=38828869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRC10602397-5A BRPI0602397C1 (pt) | 2006-04-20 | 2006-04-20 | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20100062059A1 (pt) |
| EP (1) | EP2010164A4 (pt) |
| BR (1) | BRPI0602397C1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101584853B1 (ko) * | 2013-05-16 | 2016-01-15 | 이화여자대학교 산학협력단 | 지방간 예방 또는 치료용 약학적 조성물 |
| AU2014296415B2 (en) * | 2013-07-31 | 2019-11-21 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of fatty acid metabolism disorders |
| CN103849466B (zh) * | 2014-04-01 | 2015-08-19 | 合肥工业大学 | 一种耐候耐迁移长效型微胶囊香精及其制备方法 |
| US20180050078A1 (en) * | 2015-03-03 | 2018-02-22 | KOHJIN Life Sciences Co., Ltd. | Composition for improving or preventing nonalcoholic fatty liver |
| JP7032027B2 (ja) | 2015-11-06 | 2022-03-08 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 脂肪酸代謝障害の治療を目的とした組成物および方法 |
| TW201828932A (zh) * | 2016-11-09 | 2018-08-16 | 美商諾沃麥迪斯有限責任公司 | 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法 |
| WO2021089752A1 (en) * | 2019-11-07 | 2021-05-14 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| CN113455609A (zh) * | 2021-07-02 | 2021-10-01 | 东北农业大学 | 一种糖基化亚硝基血红蛋白的制备及其在乳化肠中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900719A (en) * | 1988-08-05 | 1990-02-13 | The Ohio State University | Nitrosothiols as hypotensive agents |
| US5380758A (en) * | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| US6180139B1 (en) * | 1998-12-04 | 2001-01-30 | Viva America Marketing, Inc. | Composition and method for treating nonalcoholic steatohepatitis |
| US7235625B2 (en) * | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
| AR049142A1 (es) * | 2004-06-07 | 2006-06-28 | Wyeth Corp | Composiciones para recubrimientos de azucar,composiciones recubiertas y metodos para la fabricacion de los mismos |
-
2006
- 2006-04-20 BR BRC10602397-5A patent/BRPI0602397C1/pt not_active Application Discontinuation
-
2007
- 2007-04-20 EP EP07719267A patent/EP2010164A4/en not_active Withdrawn
- 2007-04-20 US US12/226,406 patent/US20100062059A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100062059A1 (en) | 2010-03-11 |
| EP2010164A4 (en) | 2009-11-25 |
| BRPI0602397C1 (pt) | 2009-11-24 |
| EP2010164A1 (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sayin et al. | Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist | |
| Jourova et al. | Human gut microbiota plays a role in the metabolism of drugs. | |
| Gold et al. | A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies | |
| Yin et al. | Metabolic triad in brain aging: mitochondria, insulin/IGF-1 signalling and JNK signalling | |
| Shulman et al. | Gender disparities in Parkinson’s disease | |
| BRPI0719821B8 (pt) | composição estável na armazenagem apropriada para administração a pacientes | |
| Gaschott et al. | Tributyrin, a stable and rapidly absorbed prodrug of butyric acid, enhances antiproliferative effects of dihydroxycholecalciferol in human colon cancer cells | |
| EA200900626A1 (ru) | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями | |
| MA29860B1 (fr) | Modulateurs du metabolisme et le traitement de troubles s'y rapportant | |
| BRPI0819690B8 (pt) | uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| BR112013007442A2 (pt) | polipeptídeos construídos tendo duração de ação realçada | |
| EP2037739A4 (en) | BENZYL-SUBSTITUTED POSITIVE ALLOSTERIC CHINOLON M1 RECEPTOR MODULATORS | |
| BRPI0907028B8 (pt) | uso de 17a-acetóxi-11ß-[4-n,n-dimetilamino-fenil)-19-norpregna-4,9-dieno-3,20-diona | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112014015274A8 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
| BRPI0602397A (pt) | uso e formulações de agentes nitrosantes para o tratamento da doença gordurosa do fìgado | |
| Sun et al. | Pregnenolone inhibits osteoclast differentiation and protects against lipopolysaccharide-induced inflammatory bone destruction and ovariectomy-induced bone loss | |
| Cao et al. | Anti‑inflammatory effect of Resolvin D1 on LPS‑treated MG‑63 cells Corrigendum in/10.3892/etm. 2019.8021 | |
| BR112012020377A2 (pt) | utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial | |
| NO20075758L (no) | Polymorfer av 3-0-(3',3'-dimetylsuccinyl) betulin syre di-N-metyl-D-glukamin | |
| Chen et al. | Connective tissue growth factor in hepatocytes is elevated by carbon tetrachloride via STAT3 activation | |
| Gulzar et al. | Therapeutic strategies for Huntington’s disease: Current approaches and future direction | |
| Rytting et al. | Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells | |
| Tsourdi et al. | Pros and cons of skeletal medications in the COVID-19 era |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP (BR/SP Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: TRANSFERIDO PARTE DOS DIREITOS DE: UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP |
|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001 Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B11Q | Dismissal: the certificate of addition was not accessory to any patent, or a patent which was nominated accessory and no longer exists |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |
|
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |
Free format text: ADDITIONAL INVENTOR'S CERTIFICATE: |